Table 2.
Description of the population (COVID-19 history).
| COVID-19 history | Pregnant women with a confirmed SARS-CoV-2 infection (n = 926) |
|---|---|
| Timing of exposure—no (%) | |
| < 20 WG | 89 (9.6) |
| Median GA at exposure WG (IQR) | 12 (9–16) |
| > 20 WG | 826 (89.2) |
| Median GA at exposure WG (IQR) | 38 (34–40) |
| Unknown | 11 (1.2) |
| Clinical manifestation—no (%) | |
| Asymptomatic | 295 (31.9) |
| Fever | 300 (32.4) |
| Cough | 374 (40.4) |
| Dyspnea | 146 (15.8) |
| Sore throat | 83 (9.0) |
| Myalgia | 148 (16.0) |
| Fatigue | 191 (20.6) |
| Headache | 121 (13.1) |
| Nausea/vomiting | 48 (5.2) |
| Anosmia/ageusia | 165 (17.8) |
| Other | 81 (8.8) |
| Maternal outcomes—no (%) | |
| No adverse outcomes | 828 (89.4) |
| Mild adverse outcomes | 6 (0.6) |
| Severe adverse outcomes | 92 (9.9) |
| Maternal deaths | 6 (0.6) |
| Admission to ICU | 37 (4.0) |
| Advanced oxygen support | 68 (7.3) |
First trimester was defined from 1 to 13 6/7 weeks’ gestation (WG), second trimester from 14 0/7 to 27 6/7 WG and third trimester from 28 WG. For symptomatic patients, trimester of exposure was defined as the gestational age (GA) at onset of symptoms. For asymptomatic patients, the trimester of exposure was defined as the GA at SARS-CoV-2 testing.
For symptomatic patients, the trimester of exposure was defined as the gestational age (GA) at onset of symptoms. For asymptomatic patients, the trimester of exposure was defined as the GA at SARS-CoV-2 testing.
IQR, interquartile range; ICU, Intensive Care Unit; WG, weeks’ gestation.